VIYASH

Viyash Scientific Share Price

 

 

Invest in Viyash Scientific with 2.12X leverage

Invest with MTF

Performance

  • Low
  • ₹210
  • High
  • ₹224
  • 52 Week Low
  • ₹117
  • 52 Week High
  • ₹258
  • Open Price₹211
  • Previous Close₹212
  • Volume861,282
  • 50 DMA₹208.35
  • 100 DMA₹205.42
  • 200 DMA₹196.41

Investment Returns

  • Over 1 Month + 13.95%
  • Over 3 Month -3.63%
  • Over 6 Month + 25.6%
  • Over 1 Year + 50.67%

Smart Investing Starts Here Start SIP with Viyash Scientific for Steady Growth!

Invest Now

Viyash Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 125.5
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 9,639
  • P/B Ratio
  • 11.4
  • Average True Range
  • 9.51
  • EPS
  • 2.99
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.66
  • RSI
  • 58.4
  • MFI
  • 70.71

Viyash Scientific Financials

Viyash Scientific Technicals

EMA & SMA

Current Price
₹220.76
+ 9.2 (4.35%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹210.05
  • 50 Day
  • ₹208.35
  • 100 Day
  • ₹205.42
  • 200 Day
  • ₹196.41

Resistance and Support

218.41 Pivot Speed
  • R3 240.02
  • R2 232.03
  • R1 226.40
  • S1 212.78
  • S2 204.79
  • S3 199.16

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd. is a leading animal health company in India, specializing in the manufacturing of veterinary pharmaceuticals, including APIs and formulations. It serves global markets with a strong focus on quality, compliance, and innovation.

Viyash Scientific Ltd has an operating revenue of Rs. 2,125.52 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 3% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 7% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Viyash Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-14 Quarterly Results
2025-08-08 Quarterly Results
2025-05-20 Audited Results & Final Dividend
2025-02-11 Quarterly Results
Date Purpose Remarks
2021-09-10 FINAL Rs.0.50 per share(25%)Final Dividend
View Viyash Scientific Dividend History Arrow

Viyash Scientific F&O

Viyash Scientific Shareholding Pattern

61.41%
5.82%
3.16%
19.24%
10.37%

About Viyash Scientific

  • NSE Symbol
  • VIYASH
  • BSE Symbol
  • 512529
  • Managing Director & CEO
  • Mr. Rajaram Narayanan
  • ISIN
  • INE807F01027

Similar Stocks to Viyash Scientific

Viyash Scientific FAQs

Viyash Scientific share price is ₹220 As on 18 February, 2026 | 01:38

The Market Cap of Viyash Scientific is ₹9638.8 Cr As on 18 February, 2026 | 01:38

The P/E ratio of Viyash Scientific is 125.5 As on 18 February, 2026 | 01:38

The PB ratio of Viyash Scientific is 11.4 As on 18 February, 2026 | 01:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23